Oculis Secures EMA PRIME Designation for Privosegtor, Advances Key Clinical Trials
OCS has more than doubled off its 52-week low of $16.
Summary
Oculis announced significant progress across its pipeline, including the European Medicines Agency (EMA) granting PRIME designation to Privosegtor, a key regulatory milestone that could expedite its development. Additionally, the company completed the last patient last visit (LPLV) in its Phase 3 DIAMOND program for OCS-01 in diabetic macular edema (DME), with topline results expected in June 2026. While the release reported Q1 2026 financial results, no specific numbers were provided. The update also noted upcoming topline results for Licaminlimab in dry eye disease around year-end and reiterated the previously announced FDA Special Protocol Assessment (SPA) agreement for PIONEER-1. These clinical and regulatory advancements are material for the company's valuation and future prospects.
At the time of this announcement, OCS was trading at $32.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $16.00 to $34.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.